ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,69
0,14%
Dow Jones
43 297,03
0,91%
DAX
19 848,77
-0,34%
Brent Oil
73,375
0,12%
Bitcoin
98 728,46
-0,58%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Vigil Neuroscience Inc (VIGL)

  7. Vigil Neuroscience Inc (VIGL) Actualités

VIGL

Vigil Neuroscience (VIGL)

Vigil Neuroscience Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:VIGL
DateHeureSourceTitreSymboleSociété
20/12/202400h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
14/11/202416h00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:VIGLVigil Neuroscience Inc
12/11/202413h00GlobeNewswire Inc.Vigil Neuroscience to Present at Upcoming Investor ConferencesNASDAQ:VIGLVigil Neuroscience Inc
07/11/202413h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIGLVigil Neuroscience Inc
07/11/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
07/11/202413h00GlobeNewswire Inc.Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
05/11/202413h00GlobeNewswire Inc.Vigil Neuroscience to Present at Guggenheim Healthcare Innovation ConferenceNASDAQ:VIGLVigil Neuroscience Inc
10/10/202400h22Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:VIGLVigil Neuroscience Inc
19/09/202423h20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VIGLVigil Neuroscience Inc
17/09/202413h00GlobeNewswire Inc.Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927NASDAQ:VIGLVigil Neuroscience Inc
16/09/202422h05GlobeNewswire Inc.Vigil Neuroscience to Present at Cantor Global Healthcare ConferenceNASDAQ:VIGLVigil Neuroscience Inc
29/08/202413h00GlobeNewswire Inc.Vigil Neuroscience to Present at Upcoming September Investor ConferencesNASDAQ:VIGLVigil Neuroscience Inc
13/08/202413h00GlobeNewswire Inc.Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
12/08/202423h02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:VIGLVigil Neuroscience Inc
01/08/202422h05GlobeNewswire Inc.Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology GeneticsNASDAQ:VIGLVigil Neuroscience Inc
30/07/202422h05GlobeNewswire Inc.Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)  NASDAQ:VIGLVigil Neuroscience Inc
24/07/202413h00GlobeNewswire Inc.Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s DiseaseNASDAQ:VIGLVigil Neuroscience Inc
18/07/202422h05GlobeNewswire Inc.Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International ConferenceNASDAQ:VIGLVigil Neuroscience Inc
18/07/202413h00GlobeNewswire Inc.Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSPNASDAQ:VIGLVigil Neuroscience Inc
27/06/202408h00GlobeNewswire Inc.Vigil Neuroscience Announces $40 Million Strategic Investment from SanofiNASDAQ:VIGLVigil Neuroscience Inc
30/05/202413h05GlobeNewswire Inc.Vigil Neuroscience to Present in Upcoming June Investor ConferencesNASDAQ:VIGLVigil Neuroscience Inc
08/05/202413h40GlobeNewswire Inc.Vigil Neuroscience to Present at The Citizens JMP Life Sciences ConferenceNASDAQ:VIGLVigil Neuroscience Inc
07/05/202422h05GlobeNewswire Inc.Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
17/04/202422h05GlobeNewswire Inc.Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
26/03/202412h05GlobeNewswire Inc.Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
20/03/202412h05GlobeNewswire Inc.Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical OfficerNASDAQ:VIGLVigil Neuroscience Inc
13/03/202412h05GlobeNewswire Inc.Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
12/03/202412h05GlobeNewswire Inc.Vigil Neuroscience to Present at Stifel 2024 Virtual CNS DaysNASDAQ:VIGLVigil Neuroscience Inc
06/03/202422h25GlobeNewswire Inc.Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024NASDAQ:VIGLVigil Neuroscience Inc
29/02/202422h05GlobeNewswire Inc.Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024NASDAQ:VIGLVigil Neuroscience Inc
 Showing the most relevant articles for your search:NASDAQ:VIGL

Dernières Valeurs Consultées

COIN
XRPUSD
Ripple
EU
VK
Vallourec
EU
HO
Thales
NYSE
JPM
JP Morgan Chase
NASDAQ
GOOGL
Alphabet
EU
RI
Pernod Ricard
COIN
SOLUSD
Solana
NYSE
DIS
Walt Disney
EU
LR
Legrand
EU
PX1
CAC 40
EU
ORA
Orange
COIN
AVAXUSD
Avalanche
EU
ML
Michelin
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés